The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans

The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans

Blog Article

Summary: Non-human primates (NHP) are widely used for the pre-clinical assessment of antiretrovirals (ARVs) for HIV treatment and prevention.However, the utility of these models is questionable given the differences in ARV pharmacology between humans and macaques.Here, we report a model based on ex vivo ARV exposure and the challenge of mucosal tissue explants to define pharmacological differences between CAL/MAG STRAWBERRY NHPs and humans.

For colorectal and cervicovaginal explants in both species, high concentrations of tenofovir (TFV) and maraviroc were predictive of anti-viral efficacy.However, their combinations resulted in increased inhibitory potency in NHP when Catch compared to human explants.In NHPs, higher TFV concentrations were measured in colorectal versus cervicovaginal explants (p = 0.

042).In humans, this relationship was inverted with lower levels in colorectal tissue (p = 0.027).

TFV-resistance caused greater loss of viral fitness for HIV-1 than SIV.This, tissue explants provide an important bridge to refine and appropriately interpret NHP studies.